Enhancing the reputation of the pharmaceutical industry, improving access to innovative medicines for NHS patients and ensuring a UK environment that enables the Life Sciences industry to thrive are the three key priorities for Lisa Anson as she begins her two-year Presidency of the Association of the British Pharmaceutical Industry.
The AstraZeneca UK Country President formally took over the role from John Kearney of Amgen yesterday at the Annual ABPI Conference [27th April].
Setting out her bold and ambitious mind set, Anson told delegates that the industry needed to do much more to highlight its value to patients and the UK economy. She said it should be prepared to call out poor behaviour by the few, which causes irreparable damage to the entire industry.
Speaking at the Conference, ABPI President,
Lisa Anson, said:
"Our reputation is of vital importance to the future health of the nation, and productivity of the NHS and UK. While Government, the NHS and patient groups all recognise the important steps taken in recent years to improve transparency in our sector, we must now build on that work. We should do much more to highlight the positive contributions of our industry. We must also be prepared to call out poor behaviour and separate ourselves from profiteering. This does irreparable damage to our reputation and the trust we want to promote."
Anson also said she will focus on improving NHS patient access to innovative, life-changing medicines. Noting that the NHS is one of the most cost-effective health services in the world, she highlighted that the UK is sixth lowest out of the G7 nations for investment in healthcare. The UK spends 9.9% of Gross Domestic Product on healthcare, with only Italy spending less. Anson argues that this shows a lack of ambition to improve UK patient health outcomes.
"I'm passionate about seeing tangible improvements in patient access to innovative, cost-effective medicines. Industry, Government and the NHS need to partner on a streamlined system of medicines access that values innovation and holds the NHS and industry to account for improving patient outcomes."
Anson's third priority is to create an environment that ensures UK life sciences can thrive through an effective Industrial Strategy and is open to making the most of the new opportunities created by Brexit. She joins the ABPI at a critical time as it focuses on representing its members in negotiations to help shape the future of the sector outside of the EU and works with government to develop a Life Science strategy which puts the industry as a key strategic partner in the government's future economic plans.
ABPI's Chief Executive, Mike Thompson, said:
“Lisa’s knowledge and experience will be important as we head into one of the industry’s most challenging eras to date. Lisa will play a leading role as we negotiate the future of our industry outside of the European Union, look to secure and industrial strategy that cements the UK’s position as a leading global hub for life sciences and deliver world class healthcare to the NHS through better use of innovative medicines.”
Lisa Anson brings significant experience to the role having held a variety of senior management roles at AstraZeneca in the US and the UK. She worked in a California based healthcare company and as a management consultant with KPMG. She holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University.
 ONS Digital, http://visual.ons.gov.uk/how-does-uk-healthcare-spending-compare-internationally/
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.